Sales representatives pushed the drug, linked to weight gain and diabetes, to
primary-care and nursing-home doctors while ignoring its risks, Bloomberg News
said, citing documents filed in a lawsuit by Alaska.

The drugs also were recommended for patients who weren't diagnosed with
schizophrenia or bipolar disorder, Bloomberg News reported, citing complaints
filed by Montana and Mississippi.